Clinical Trial Update: Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating ILX651 in patients with castration-resistant prostate cancer who were previously treated with docetaxel.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ILX651

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hormone-refractory Prostate Cancer | Phase 2 | Status: COMPLETED